Clinical Trial Finds Achilles Tendon Injections Offer No Meaningful Long-Term Benefit Over Placebo

Persistent lower-limb discomfort affecting the Achilles tendon is a widespread clinical challenge, impacting everyday activities such as walking for approximately six percent of individuals during their lifetimes. While supervised exercise routines and activity modifications remain foundational recommendations, a significant portion of patients do not fully recover, prompting many to explore alternative interventions including injection therapies. A recent randomized controlled trial published in The BMJ has investigated whether high-volume injections delivered around the tendon provide meaningful clinical advantages.

Evaluating High-Volume Injections and Corticosteroids

The investigation enrolled 192 adult participants presenting with midportion Achilles tendinopathy at a radiology clinic in Melbourne, Australia. Researchers tracked subjects with a mean age of 49 years, where 55 percent of the group identified as male. Participants were randomly distributed across three distinct arms: a sham injection group, a high-volume injection group without corticosteroids, and a high-volume injection group containing corticosteroids. Every participant received standard exercise programs, education, and activity modification guidance alongside their assigned procedure.

Investigators primarily measured self-reported pain and functional disability at 52 weeks utilizing the Victoria Institute of Sport Assessment-Achilles scale, which scores from zero to one hundred where a higher number indicates less impairment. At the start of the study, participants reported moderate to severe symptoms with a mean score of 48.7 and a median symptom duration spanning two years. Out of the original cohort, 181 individuals completed follow-up assessments at the 12-month mark.

Trial Findings and Clinical Limitations

The final data revealed no notable differences in pain and disability between the sham procedure and either high-volume injection method at 12 months. Specifically, injections containing no corticosteroids demonstrated no superior effect over the placebo group at any observed time point. While formulations containing corticosteroids yielded minor, short-term relief at six weeks compared to the sham group, they paradoxically resulted in worse outcomes at 26 weeks when compared directly against high-volume injections administered without corticosteroids. No serious adverse events related to the trial procedures were documented.

Study authors noted several limitations within their design, including recruiting participants primarily through social media platforms which could restrict the broader generalizability of the findings. Additionally, investigators were unable to mask the clinicians performing the injections, and researchers noted a residual risk that some observed variances might reflect chance rather than true therapeutic effects. Despite these caveats, the authors suggest the findings should encourage clinicians to carefully review the rationale behind utilizing such injections for persistent lower-limb discomfort.

Perspectives on Informed Consent

In an accompanying editorial, specialists emphasized that pharmacological agents such as corticosteroids carry nuanced trade-offs and must be reserved strictly for contexts where short-term relief outweighs potential long-term uncertainties. Experts highlighted that patients should be explicitly informed that these interventions do not constitute a cure for tendinopathy. Comprehensive discussions covering the broader clinical overview remain an essential component of the informed consent process before moving forward with injection therapies.

• Randomized controlled trial involving 192 participants evaluated injection efficacy at 12 months.
• High-volume injections with or without corticosteroids showed no significant long-term benefit over sham treatments.
• Experts stress that thorough patient communication regarding treatment limitations is vital during informed consent.